Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

S. Korea Attracts Local Subsidiary Of Italian Drug Maker Bracco

This article was originally published in PharmAsia News

Executive Summary

A South Korean subsidiary of Italy's Bracco Imaging launched operations in the country to provide medical-contrast media. As South Korea's first Italian pharmaceutical firm, Bracco Korea plans to compete with other foreign rivals, including Bayer Schering Pharma and GE Healthcare. Until Bracco's decision to set up shop in South Korea, its products had been marketed by Ilsung Pharmaceutical, a local drug maker. (Click here for more

You may also be interested in...



Coronavirus Update: After UK Nod, New Forecast Makes Pfizer Vaccine The Leader

After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer's COVID-19 vaccine in 2021 and beyond.

Compare And Contrast: New UKCA Marking System Will Stress Safety, Quality and Agility

How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.

China Preps For First COVID Vaccine Roll-Outs

Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers. 

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel